Ablation Falls Short in Oligometastatic Breast Cancer Trial October 09, 2026

https://www.medscape.com/viewarticle/ablation-falls-short-oligometastatic-breast-cancer-trial-2026a10011zk?src= Adding metastasis-directed ablation to first-line systemic therapy did not improve progression-free or overall survival in patients with oligometastatic breast cancer. Two-year overall survival estimates were 88.4% with systemic therapy alone and 78% with ablation.